Results 311 to 320 of about 2,334,067 (354)
Some of the next articles are maybe not open access.

Peptoids as endothelin receptor antagonists

Bioorganic & Medicinal Chemistry Letters, 2001
A series of new peptoids as endothelin receptor antagonists has been synthesized. Screening them for their ability to bind with endothelin receptors (ET(A) and ET(B)) competitively in the presence of (125I) endothelin led to the discovery of compounds as possible leads with IC50s in the low micromolar concentrations.
Simi Sarin   +5 more
openaire   +3 more sources

Endothelins—from receptors to medicine

Trends in Pharmacological Sciences, 1993
Since the discovery of endothelins, peptides with exceptional vasoconstrictor potency that were originally suggested to act by causing the opening of Ca2+ channels, it has emerged that these agents are important in intercellular communication in many tissues.
R.C. Miller, J.T. Pelton, J.P. Huggins
openaire   +3 more sources

Endothelins and endothelin receptor antagonists: Binding to plasma proteins

Life Sciences, 1996
Endothelins (ET) are 21-amino acid peptides that bind to membrane receptors to initiate a wide range of pathophysiological effects. PD-156707, L-749329, Ro-470203, and A-127722 are potent non-peptide ET receptor antagonists developed recently. When tested in human and rat plasma, both ET-1 and -3 and the four aforementioned antagonists exhibited a high
Jinshyun R. Wu-Wong   +5 more
openaire   +3 more sources

Role of endothelin and endothelin receptor antagonists in renal disease

European Journal of Clinical Investigation, 2006
AbstractEndothelin (ET)‐1 is a potent vasoconstrictor peptide with pro‐inflammatory, mitogenic, and pro‐fibrotic properties that is closely involved in both normal renal physiology and pathology. ET‐1 exerts a wide variety of biological effects, including constriction of cortical and medullary vessels, mesangial cell contraction, stimulation of ...
W. Neuhofer, D. Pittrow
openaire   +3 more sources

Pharmacology of Renal Endothelin Receptors

2011
Endothelin (ET)-1 is the major isoform in the human kidney where it interacts with two G protein-coupled receptors, ET(A) and ET(B). It contains high densities of ET receptors, but in contrast to most other peripheral organs, the majority (70%) are of the ET(B) subtype and largely have a differential distribution to ET(A) receptors within renal cells ...
Janet J. Maguire, Anthony P. Davenport
openaire   +3 more sources

Endothelin Receptor Antagonists

2015
Endothelin-1 (ET-1) is a potent vasoconstrictor and mitogen that is secreted by the endothelium. Pulmonary vascular expression of endothelin is increased in pulmonary hypertension and plasma levels correlate with the severity of disease. Several endothelin receptor antagonists (ERAs) have been developed and are available for the treatment of pulmonary ...
Richard N. Channick   +1 more
openaire   +2 more sources

Endothelin Receptor Antagonist

2017
Endothelin (ET)-1, a peptide mainly produced by vascular endothelial cells, has potent and long-lasting vasoconstrictive effect. In addition, ET-1 has been shown to induce a variety of biological effects including cell proliferation, inflammation, and fibrosis.
Noriaki Emoto, Noriaki Emoto
openaire   +2 more sources

Novel Endothelin Receptors

1998
Since the original discovery of endothelin (ET) by Yanagisawa et al in 1988,1 the scientific interest in this area of research has grown exponentially. It was originally hypothesized that ET interacts with two subtypes of receptors to mediate its biological functions and subsequent cloning of two ET receptors confirmed the original hypothesis.
openaire   +2 more sources

Cloning and expression of a cDNA encoding an endothelin receptor

Nature, 1990
H. Arai   +4 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy